- The medical device company sprouts SaaS-like metrics; 30%+ growth, 80% recurring revenues, 80%+ gross margin and it’s profitable and cash flow positive.
- The big sales force expansion depress these figures now, but will create a tremendous ratcheting up effect later.
- There are multiple expansion opportunities like overseas and other devices.
The Zynex Party Has Much Further To Go
June 10th, 2019 · No Comments